Who Needs Closer Monitoring for Tysabri-Related PML?

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Information to Targeted Risk Communication

If you or a loved one is taking Tysabri, you may be concerned about the risk of progressive multifocal leukoencephalopathy (PML). Clinical reports have identified specific factors that increase the need for closer monitoring. Building on a foundation of patient safety research, this page summarizes the documented risk factors and red flags associated with Tysabri-related PML.

Medical Evidence: Tysabri and PML Risk

Tysabri (natalizumab) is a biologic therapy approved for the treatment of relapsing forms of multiple sclerosis and Crohn's disease. Its use is associated with a significantly increased risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic viral infection of the brain caused by the JC virus (JCV). PML typically occurs only in immunocompromised patients and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The U.S. Food and Drug Administration has assigned a boxed warning to Tysabri due to this risk, emphasizing that healthcare professionals must monitor patients closely and withhold the drug immediately at the first sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Clinical presentation and diagnosis of PML are critical for early intervention. Symptoms may include progressive weakness on one side of the body, clumsiness, visual disturbances, changes in thinking, memory, and personality, and, in later stages, seizures. Diagnosis typically involves brain MRI showing characteristic white matter lesions and detection of JCV DNA in cerebrospinal fluid via polymerase chain reaction. In clinical trials, PML occurred in three patients who received Tysabri: two among 1,869 multiple sclerosis patients treated for a median of 120 weeks (both had also received interferon beta-1a), and one among 1,043 Crohn's disease patients after eight doses (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These cases underscore the latency between exposure and documented harm, which can range from months to years.

Mechanism of Action and Risk Factors

The mechanistic pathway linking Tysabri to PML involves its pharmacological action. Tysabri is a monoclonal antibody that binds to alpha-4 integrins on the surface of immune cells, preventing their migration across the blood-brain barrier into the central nervous system. This reduces inflammation in conditions like multiple sclerosis but also impairs immune surveillance against JCV, which is latent in many individuals. Reactivation of JCV in the brain leads to lytic infection of oligodendrocytes, causing demyelination and the clinical syndrome of PML. The risk is amplified by three established factors: the presence of anti-JCV antibodies (indicating prior exposure to the virus), longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be weighed against expected benefits when initiating or continuing therapy.

Adequacy of Warnings and Litigation Context

Adequacy of warnings regarding Tysabri and PML has been a central issue in litigation. The boxed warning clearly states that Tysabri increases the risk of PML and that it usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). It also mandates that Tysabri be available only through a restricted distribution program called the TOUCH Prescribing Program, which requires prescribers, patients, and pharmacies to enroll and adhere to monitoring protocols (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these measures, some patients and their families have alleged that the warnings were insufficient or that the risks were not adequately communicated, leading to lawsuits. Settlement-related considerations for affected patients often involve the severity of PML outcomes, the timing of diagnosis relative to treatment initiation, and whether the patient had identifiable risk factors that should have prompted earlier discontinuation.

Timeline and Prognosis of PML

The timeline between Tysabri exposure and documented PML harm varies. In clinical trials, PML occurred after a median of 120 weeks in multiple sclerosis patients and after eight doses in one Crohn's disease patient (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Post-marketing data indicate that risk increases with cumulative exposure, particularly beyond two years. For patients who develop PML, the prognosis is poor, with most experiencing severe neurological deficits or death. Early diagnosis and prompt discontinuation of Tysabri, along with plasma exchange to accelerate drug clearance, may improve outcomes but do not guarantee recovery.

Settlement Criteria and Evidence Summary

In summary, the evidence demonstrates a clear causal link between Tysabri and PML, with well-defined risk factors and a latency period that can extend over years. The boxed warning and TOUCH program represent regulatory efforts to mitigate risk, but litigation has arisen over whether these measures were adequate. For affected patients, settlement criteria typically consider the severity of harm, the presence of risk factors, and the timing of diagnosis. Healthcare providers must remain vigilant in monitoring for PML symptoms and in discussing risks with patients. References (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Tysabri and how is it linked to PML?

Tysabri (natalizumab) is a biologic therapy for multiple sclerosis and Crohn's disease. It increases the risk of progressive multifocal leukoencephalopathy (PML), a severe brain infection caused by the JC virus. The FDA has issued a boxed warning for this risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What are the settlement criteria for Tysabri-related PML lawsuits?

Settlement criteria typically consider the severity of PML outcomes, the timing of diagnosis relative to treatment initiation, and whether the patient had identifiable risk factors such as anti-JCV antibodies, longer treatment duration, or prior immunosuppressant use. Each case is evaluated individually.

How long after starting Tysabri can PML develop?

PML can develop months to years after starting Tysabri. In clinical trials, it occurred after a median of 120 weeks in MS patients and after eight doses in one Crohn's patient (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Risk increases with longer exposure, especially beyond two years.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed - Tysabri Label

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.